| Product Code: ETC6575690 | Publication Date: Sep 2024 | Updated Date: Apr 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Burkina Faso continues to rely on imports for non-small cell lung cancer therapeutics, with top exporters in 2024 being India, France, Ghana, Morocco, and China. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market. Despite a slight decline in the compound annual growth rate (CAGR) from 2020-2024, there was a notable growth rate of 10.24% from 2023-2024. This suggests potential opportunities for market expansion and diversification in the coming years within Burkina Faso`s non-small cell lung cancer therapeutics sector.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Overview |
3.1 Burkina Faso Country Macro Economic Indicators |
3.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, 2022 & 2032F |
3.3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market - Industry Life Cycle |
3.4 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market - Porter's Five Forces |
3.5 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume Share, By Therapy, 2022 & 2032F |
3.6 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume Share, By Distribution Channel, 2022 & 2032F |
3.7 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume Share, By Cancer Type, 2022 & 2032F |
4 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about non-small cell lung cancer (NSCLC) in Burkina Faso |
4.2.2 Growing investments in healthcare infrastructure and facilities |
4.2.3 Advancements in medical research and technology for NSCLC treatment |
4.3 Market Restraints |
4.3.1 Limited access to advanced NSCLC therapies and treatments |
4.3.2 High treatment costs and limited healthcare coverage for NSCLC patients in Burkina Faso |
5 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Trends |
6 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market, By Types |
6.1 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market, By Therapy |
6.1.1 Overview and Analysis |
6.1.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Therapy, 2022 - 2032F |
6.1.3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Targeted Therapy, 2022 - 2032F |
6.1.4 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Immunotherapy, 2022 - 2032F |
6.1.5 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Chemotherapy, 2022 - 2032F |
6.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market, By Distribution Channel |
6.2.1 Overview and Analysis |
6.2.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Hospital Pharmacies, 2022 - 2032F |
6.2.3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Retail Pharmacies, 2022 - 2032F |
6.2.4 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Online Pharmacies, 2022 - 2032F |
6.2.5 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Others, 2022 - 2032F |
6.3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market, By Cancer Type |
6.3.1 Overview and Analysis |
6.3.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Adenocarcinoma, 2022 - 2032F |
6.3.3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Squamous cell carcinoma, 2022 - 2032F |
6.3.4 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenues & Volume, By Large cell carcinoma, 2022 - 2032F |
7 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Import-Export Trade Statistics |
7.1 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Export to Major Countries |
7.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Imports from Major Countries |
8 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Key Performance Indicators |
8.1 Number of NSCLC patients diagnosed at an early stage |
8.2 Availability and utilization rate of NSCLC screening programs |
8.3 Percentage of NSCLC patients receiving recommended treatment protocols |
8.4 Adoption rate of innovative NSCLC therapies in Burkina Faso |
8.5 Survival rates of NSCLC patients in Burkina Faso |
9 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market - Opportunity Assessment |
9.1 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Opportunity Assessment, By Therapy, 2022 & 2032F |
9.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Opportunity Assessment, By Distribution Channel, 2022 & 2032F |
9.3 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Opportunity Assessment, By Cancer Type, 2022 & 2032F |
10 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market - Competitive Landscape |
10.1 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Revenue Share, By Companies, 2025 |
10.2 Burkina Faso Non-Small Cell Lung Cancer Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here